Cargando…

PCSK9 inhibition in high-risk patients

Detalles Bibliográficos
Autores principales:	Zijlstra, Laurien E., Mooijaart, Simon P., Jukema, J. Wouter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6932888/ https://www.ncbi.nlm.nih.gov/pubmed/31829977 http://dx.doi.org/10.18632/aging.102621

Ejemplares similares

The association of kidney function and cognitive decline in older patients at risk of cardiovascular disease: a longitudinal data analysis
por: Zijlstra, Laurien E., et al.
Publicado: (2020)

PCSK9 Inhibition: Does Lipoprotein Size Matter?
por: Si‐Tayeb, Karim, et al.
Publicado: (2015)

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Just Price for PCSK9 Inhibitors: No less, No More
por: Nasir, Khurram
Publicado: (2018)

Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment
por: Sliz, Eeva, et al.
Publicado: (2018)

Association of cardiovascular structure and function with cerebrovascular changes and cognitive function in older patients with end-stage renal disease
por: Zijlstra, Laurien E., et al.
Publicado: (2020)

PCSK9 Inhibitors: What Lies Beyond Monoclonal Antibodies?
por: EBioMedicine
Publicado: (2015)

PCSK9 and carbohydrate metabolism: A double-edged sword
por: Filippatos, Theodosios D, et al.
Publicado: (2017)

PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
por: Carugo, Stefano, et al.
Publicado: (2022)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
por: Blom, Dirk J, et al.
Publicado: (2016)

Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk
por: Behr, Paulo Eduardo Ballvé, et al.
Publicado: (2018)

PCSK9 as an Atherothrombotic Risk Factor
por: Sotler, Tadeja, et al.
Publicado: (2023)

The discovery of PCSK9 inhibitors: A tale of creativity and multifaceted translational research
por: Elguindy, Ahmed, et al.
Publicado: (2013)

PCSK9 inhibition: the way forward in the treatment of dyslipidemia
por: Stoekenbroek, Robert M., et al.
Publicado: (2015)

Lipoprotein(a) and PCSK9 inhibition: clinical evidence
por: Ruscica, Massimiliano, et al.
Publicado: (2020)

Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) on Lipid Metabolism and Insulin Resistance in Human
por: Muraki, Isao
Publicado: (2021)

Challenges with PCSK9 Inhibitors Use in Asia Given Real-World Data Implications
por: Uno-Eder, Kiyoko
Publicado: (2023)

PCSK9 and Calcific Aortic Valve Stenosis: Moving Beyond Lipids
por: Leopold, Jane A.
Publicado: (2020)

Improving the care for older emergency department patients: the Acutely Presenting Older Patient study
por: Mooijaart, Simon P.
Publicado: (2021)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Circulating miRNAs and Vascular Injury Markers Associate with Cardiovascular Function in Older Patients Reaching End-Stage Kidney Disease
por: Zhao, Qiao, et al.
Publicado: (2022)

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo
por: Schreckenberg, Rolf, et al.
Publicado: (2022)

New developments in atherosclerosis: clinical potential of PCSK9 inhibition
por: Giunzioni, Ilaria, et al.
Publicado: (2015)

PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
por: Ito, Matthew K., et al.
Publicado: (2016)

PCSK9 inhibition potentiates cancer immune checkpoint therapy
por: Liu, Xinjian, et al.
Publicado: (2020)

PCSK9 Inhibition: From Current Advances to Evolving Future
por: Liu, Chunping, et al.
Publicado: (2022)

LDL lowering effect of PCSK9 inhibition is reduced in women
por: Myasoedova, Veronika A, et al.
Publicado: (2023)

The Multifaceted Biology of PCSK9
por: Seidah, Nabil G, et al.
Publicado: (2021)

Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population
por: Cai, Gaojun, et al.
Publicado: (2018)

PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review
por: Handelsman, Yehuda, et al.
Publicado: (2018)

Application Value of PCSK9 Inhibitor in Cardiovascular High Risk Patients: A Meta-Analysis
por: Zhao, Liming, et al.
Publicado: (2023)

Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis
por: Perrot, Nicolas, et al.
Publicado: (2020)

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
por: Holla, Øystein L, et al.
Publicado: (2007)

Gene Therapy Targeting PCSK9
por: Katzmann, Julius L., et al.
Publicado: (2022)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production
por: Dong, Jianjie, et al.
Publicado: (2020)

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
por: Reyes-Soffer, Gissette, et al.
Publicado: (2017)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_73potfj01dekv600nn2qglboa6